Chronic myelogenous leukaemia (CML)
نویسندگان
چکیده
منابع مشابه
Chronic myelogenous leukaemia (CML)
Evidence exists for the involvement of the most primitive and quiescent hematopoietic stem cell compartiment (CD34+/CD38-, Thy1+): t(9;22) is found in myeloid progenitor and in B-lymphocytes progenitors, but, involvement of the T-cell lineage is extremely rare. The existence of a highly quiescent stem cell population has been demonstrated in patients with CML. More recently, the presence of Ph ...
متن کاملChronic myelogenous leukaemia (CML)
Clinics Splenomegaly; chronic phase (lasts about 3 yrs) with maintained cell’s normal activities, followed by accelerated phase(s)(blasts still < 15%), and blast crisis (BC-CML) with blast cells > 30%; blood data: WBC: 100 X 10/l and more during chronic phase, with basophilia; a few blasts; thrombocytosis may be present; low leucocyte alkaline phosphatases; typical acute leukaemia (AL) blood da...
متن کاملChronic myelogenous leukaemia in infancy.
Chronic myelogenous leukaemia is an uncommon disease in infancy and is usually termed congenital in cases seen at or within a few days after birth. The latter do not appear to differ from those seen later except that they are believed to have started during intra-uterine life, and Kelsey and Andersen (1939) have laid down certain criteria for the diagnosis, which might be briefly stated as symp...
متن کاملChronic Myelogenous Leukemia (CML) in the elderly
Published: June 1, 2014 Received: May 5, 2014 Accepted: May 6, 2014 Citation: Mediterr J Hematol Infect Dis 2014, 6(1): e2014037, DOI: 10.4084/MJHID.2014.037 This article is available from: http://www.mjhid.org/article/view/13434 This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unre...
متن کاملIdentification of Potent Inhibitors for Resistant Form of Chronic Myelogenous Leukaemia (CML)
The BCR-ABL protein is the causative agent in the pathogenesis of chronic myeloid leukemia (CML). Although there are several drugs in the market which inhibit BCR-ABL efficiently there are some cases of resistance1. Imatinib2,3, nilotinib3,4, bosutinib4 ,dasatinib5, bafetinib6 are approved tyrosine kinase inhibitors (TKI’s) and more recently, ponatinib was approved TKI which is shown to bind an...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Atlas of Genetics and Cytogenetics in Oncology and Haematology
سال: 2010
ISSN: 1768-3262
DOI: 10.4267/2042/32067